Chen et al. designed a CD13 targeting (NGR peptide) PEGylated LPD (liposome-polycation-DNA) nanoparticle (LPD-PEG-NGR) to deliver both doxorubicin and c-MYC siRNA, and they reported the enhanced cancer therapeutic effects in tumor mouse model [29]. The gene discussed is MYC; the disease is cancer.